Ellis Martin Report: Cardiol Therapeutics (CRDL.TO) CEO David Elsley Discusses Phase III MAVERIC and What Comes Next for ...
Malibu, CA, Oct 8, 2026 AEST (ABN Newswire) - Cardiol Therapeutics (TSE:CRDL) (NASDAQ:CRDL) (CT9:FRA) President and CEO David Elsley joins Ellis Martin for an update on the company's cardiovascular drug development programs, with a focus on CardiolRx …